Personalized strategies for the diagnosis and therapy of type II diabetes and obesity

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 80-109

  Müller, Günter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Copy number variants; Exosomes; Gene therapy; Genome wide associations; Glimepiride; Insulin; Lipotoxicity; Metabolic diseases; Microvesicles; Obesity; Personalized medicine; Single nucleotide polymorphisms; Type ii diabetes; White and brown adipose tissue

Indexed keywords

ADENOVIRUS VECTOR; ANTIDIABETIC AGENT; APD 597; APD597; CD34 ANTIBODY; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GFT 505; GFT505; GHRELIN; GLIBENCLAMIDE; GLIMEPIRIDE; HERPESVIRUS VECTOR; HISTONE H3; INCB1373; INCB13739; INSULIN SENSITIZING AGENT; INT 777; INTERMEDIN; LENTIVIRUS VECTOR; LIPID; LX 4211; LX4211; MBX 2982; METFORMIN; MK 0916; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PIOGLITAZONE; RECOMBINANT GLUCAGON; RETROVIRUS VECTOR; SRT 2104; SRT2104; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENO ASSOCIATED VIRUS; ANTIDIABETIC ACTIVITY; ARTICLE; BARIATRIC SURGERY; BROWN ADIPOSE TISSUE; CIRCADIAN RHYTHM; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSIS; DRUG DEVELOPMENT; ENERGY EXPENDITURE; FLORA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATION OF THE LUNGS, BRONCHI AND PLEURA; LIPID METABOLISM; LIPOTOXICITY; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMALLPOX VIRUS; SOMATIC GENE THERAPY; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; WHITE ADIPOSE TISSUE;

EID: 84860496022     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212800388950     Document Type: Article

References (313)

1. Edwards, K.L.; Hutter, CM.; Wan, J.Y.; Kim, H.; Monks, S.A. Genome-wide linkage scan for the metabolic syndrome: The GEN- NID study. Obesity, 2008, 16(7), 1596-1601.
2. Weedon, M.N.; McCarthy, M.I.; Hitman, G.; Walker, M.; Groves, C.J.; Zeggini, E. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med., 2006, 3(10), e374.
3. Romeo, S.; Pennacchio, L.A.; Fu, Y.; Boerwinkle, E.; Tybjaerg-Hansen, A.; Hobbs, H.H.; Cohen, J.C. Population-based resequenc-ing of ANGPLT4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet., 2007, 39(4), 513-516.
4. Hegele, R.A.; Cao, H.; Harris, S.B.; Hanley, A.J.G.; Zinman, B. The hepatic nuclear factor-1a G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J. Clin. Endocrinol. Metab., 1999, 84(3), 1077-1082.
5. Wildin, R.S.; Ramsdell, F.; Peake, J.; Faravelli, F.; Casanova, J. L.; Buist, N.; Levy-Lahad, E.; Mazzella, M.; Goulet, O.; Perroni, L.; Bricarelli, F. D.; Byrne, G.; McEuen, M.; Proll, S.; Appleby, M.; Brunkow, M.E. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet., 2001, 27(1), 18-20.
6. Grant, S.F.; Thorleifsson, G.; Reynisdottir, I.; Benediktsson, R.; Manolescu, A.; Sainz, J. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet, 2006, 38(3), 320-323.
7. Raeder, H.; Johansson, S.; Holm, P.I.; Haldorsen, I.S.; Mas, E.; Sbarra, V.; Nermoen, I.; Eide, S.A.; Grevle, L.; Bjorkhaug, L.; Sagen, J.V.; Aksnes, L.; Sovik, O.; Lombardo, D.; Molven, A.; Njolstad, P.R. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet, 2006, 38(1), 54-62.
8. Hegele, R.A.; Anderson, CM.; Wang, J.; Jones, D.C.; Cao, H. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res., 2000, 10(5), 652-658.
9. Capell, B.C.; Collins, F.S. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet., 2006, 7(12), 940-952.
10. Delepine, M.; Nicolino, M.; Barrett, T.; Golamaully, M.; Lathrop, G.M.; Julier, C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet., 2000, 25(4), 406-409.
11. Janssens, A.C.; Gwinn, M.; Subramonia-Lyer, S.; Khoury, M.J. Does genetic testing really improve the prediction of future type 2 diabetes? PLoS Med., 2006, 3(2), e114.
12. Xiayan, L.; Legido-Quigley, C. Advances in separation science applied to metabonomics. Electrophoresis, 2008, 29(18), 3724-3736.
13. Figeys, D.; Pinto, D. Proteomics on a chip: Promising developments. Electrophoresis, 2001, 22(2), 208-216.
14. Müller, G. Concepts and options for current insulin research and future anti-diabetic therapy. Recent Res. Develop. Endocrinol., 2002, 3(1), 199-218.
15. Pearson, E.R.; Donnelly, L.A.; Kimber, C; Whitley, A.; Doney, A.S.F.; McCarthy, M.I. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes, 2007, 56(8), 2178-2182.
16. Prokopenko, I.; McCarthy, M.J.; Lindgren, CM. Type 2 diabetes: new genes, new understanding. Trends Genet, 2008, 24(12), 613-621.
17. Ridderstrale, M.; Groop, L. Genetic dissection of type 2 diabetes. Mol. Cell. Endocrinol., 2009, 297(1-2), 10-17.
18. Lindgren, C.M. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nature Clin. Pract., 2007, 4(3), 156-163.
19. Florez, J.C. The genetics of type 2 diabetes: a realistic appraisal in 2008. J. Clin. Endocrinol. Metab., 2008, 93(12), 4633-4642.
20. Lusis, A.J.; Attie, A.D.; Reue, K. Metabolic syndrome: from epidemiology to systems biology. Nature Rev. Genet., 2008, 9(11), 819-830.
21. Gibson, G. Decanalization and the origin of complex disease. Nature, 2009, 10(2), 134-140.
22. Janssens, A.C.; van Duijn, C.M. Genome-based prediction of common diseases: advances and prospects. Hum. Mol. Genet., 2008, 17(R2), R166-R173.
23. McCarthy, M.I.; Smedley, D.; Hide, W. New methods for finding disease-susceptibility genes: impact and potential. Genome Biol., 2003, 4(10), 119.
24. Rothman, K.J.; Greenland, S. Causation and causal interference in epidemiology. Am. J. Pub. Health, 2005, 95(S1), S144-S150.
25. Sharma, A.M. The thrifty-genotype hypothesis and its implications for the study of complex genetic disorders in man. J. Mol. Med., 1998, 76(8), 568-571.
26. Pearson, H. One gene, twenty years. Nature, 2009, 460(7252), 165-169.
27. McCarthy, M.I; Hattersley, A.T. Learning from molecular genetics. Novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes, 2008, 57(11), 2889-2898.
28. Stoy, J.; Edghill, E.L.; Flanagan, S.E.; Ye, H.; Paz, V.P.; Pluzhnikov, A.; Below, J.E.; Hayes, M.G.; Cox, N.J.; Lipkind, G.M.; Lipton, R.B.; Greeley, S.A.; Patch, A.M.; Ellard, S.; Steiner, D.F.; Hattersley, A.T.; Philipson, L.H.; Bell, G.I. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl. Acad. Sci. USA, 2007, 104, 389, 15040-15044.
29. LeRoith, D.; Gavrilova, O. Mouse models created to study the pathophysiology of type 2 diabetes. Int. J. Biochem. Cell Biol., 2006, 38(5-6), 904-912.
30. Hattersley, A.T.; Turner, R.C.; Permutt, M.A.; Patel, P.; Tanizawa, Y.; Chiu, K.C.; O'Rahilly, S.; Watkins, P.J.; Wainscoat, J.S. Linkage of type 2 diabetes to the glucokinase gene. Lancet, 1992, 339(8805), 1307-1310.
31. Froguel, P.; Vaxillaire, M.; Sun, F.; Velho, G.; Zouali, H.; Butel, M.O.; Lesage, S.; Vionnet, N.; Clement, K.; Fougerousse, F.; Tanizawa, Y.; Weissenbach, J.; Beckmann, J.S.; Lathrop, G.M.; Passa, P., Permutt, M.A.; Cohen, D. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature, 1992, 356(6365), 162-164.
32. Gloyn, A.L.; Pearson, E.R.; Antcliff, J.F.; Proks, P.; Bruining, G.J.; Slingerland, A.S.; Howard, N.; Srinivasan, S.; Silva, J.M.; Molnes, J.; Edghill, E.L.; Frayling, T.M.; Temple, I.K.; Mackay, D.; Shield, J.P.; Sumnik, Z.; van Rhijn, A.; Wales, J.K.; Clark, P.; Gorman, S.; Aisenberg, J.; Ellard, S.; Njolstad, P.R.; Ashcroft, F.M.; Hattersley, A.T. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med., 2004, 350(18), 1838-1849.
33. Proks, P.; Arnold, A.L.; Bruining, J.; Girard, C.; Flanagan, S.E.; Larkin, B.; Colclough, K.; Hattersley, A.T.; Ashcroft, F.M.; Ellard, S. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum. Mol. Genet., 2006, 15(11), 1793-1800.
34. Babenko, A.P.; Polak, M.; Cave, H.; Busiah, K.; Czernichow, P.; Scharfmann, R.; Bryan, J.; Aguilar-Bryan, L.; Vaxillaire, M.; Froguel, P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med., 2006, 355(5), 456-466.
35. Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J.; Chatterjee, V.K.; O'Rahilly, S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 1999, 402(6764), 880-883.
36. Kadowaki, T.; Bevins, C.L.; Cama, A.; Ojamaa, K.; Marcus-Samuels, B.; Kadowaki, H.; Beitz, L.; McKeon, C.; Taylor, S.I. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science, 1988, 240(4853), 787-790.
37. Byrne, M.M.; Sturis, J.; Clement, K.; Vionnet, N.; Pueyo, M.E.; Stoffel, M.; Takeda, J.; Passa, P.; Cohen, D.; Bell, G.I. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J. Clin. Invest., 1994, 93(3), 1120-1130.
38. Yamagata, K.; Oda, N.; Kaisaki, P.J.; Menzel, S.; Furuta, H.; Vaxillaire, M.; Southam, L.; Cox, R.D.; Lathrop, G.M.; Boriraj, V.V.; Chen, X.; Cox, N.J.; Oda, Y.; Yano, H.; Le Beau, M.M.; Yamada, S.; Nishigori, H.; Takeda, J.; Fajans, S.S.; Hattersley, A.T.; Iwasaki, N.; Pedersen, O.; Polonsky, K.S.; Turner, R.C.; Velho, G.; Chevre, J.-C.; Froguel P.; Bell, G.I. Mutations in the hepatic nuclear factor 1 alpha gene in maturity-onset diabetes of the young (MODY3). Nature, 1996, 384(6608), 455-458.
39. Pontoglio, M.; Barra, J.; Hadchouel, M.; Doyen, A.; Kress, C.; Poggi Bach, J.; Babinet, C.; Yaniv, M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell, 1999, 84(4), 575-585.
40. Dukes, I.D.; Sreenan, S.; Roe, M.W.; Levisetti, M.; Zhou, Y.P.; Ostrega, D.; Bell, G.I.; Pontoglio, M.; Yaniv, M.; Philipson, L.; Polonsky, K.S. Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice. J. Biol. Chem., 1998, 273(38), 24457-24464.
41. Yamagata, K.; Furuta, H.; Oda, N.; Kaisaki, P.J.; Menzel, S.; Cox, N.J.; Fajans, S.S.; Signorini, S.; Stoffel, M.; Bell, G.I. Mutations in the hepatocyte nuclear factor 4 alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 1996, 384(6608), 458-460.
42. Horikawa, Y.; Iwasaki, N.; Hara, M.; Furuta, H.; Hinokio, Y.; Cockburn, B.; Lindner, T.; Yamagata, K.; Ogata, M.; Tomonaga, O.; Kuroki, H.; Kasahar, T.; Iwamoto, Y.; Bell, G.I. Mutation in hepatocyte nuclear factor-1b gene (TCF2) associated with MODY. Nat. Genet., 1997, 17(4), 384-385.
43. Servitja, J.M.; Ferrer, J. Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia, 2004, 47(4), 597-613.
44. Maestro, M.A.; Cardalda, C.; Boj, S.F.; Luco, R.F.; Servitja, J.M.; Ferrer, J. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr. Dev., 2007, 12, 33-45.
45. McAllister, E.J.; Dhurandhar, N.V.; Keith, S.W.; Aronne, L.J.; Barger, J.; Baskin, M.; Benca, R.M.; Biggio, J.; Boggiano, M.M.; Eisenmann, J.C.; Elobeid, M.; Fontaine, K.R.; Gluckman, P.; Han-lon, E.C.; Katzmarzyk, P.; Pietrobelli, A.; Redden, D.T.; Ruden, D.M.; Wang, C.; Waterland, R.A.; Wright, S.M.; Allison, D.B. Ten putative contributors to the obesity epidemic. Crit. Rev. Food Sci. Nutr., 2009, 49(10), 868-913.
46. Powell, A.G.; Apovian, C.M.; Aronne, L.J. New drug targets for the treatment of obesity. Clin. Pharmacol. Therapeut., 2011, 90(1), 40-51.
47. Burke L.E.; Wang, J. Treatment strategies for overweight and obesity. J. Nursing Scholarship, 2011, 43(4), 1-8.
48. Jain, R.; Chung, S.M.; Jain, L.; Khurana, M.; lau, S.W.J.; Lee, J.E.; Vaidyanathan, J.; Zadezensky, I.; Choe, S.; Sahajwalla, C.G. Implications of obesity for drug therapy: Limitations and challenges. Clin. Pharmacol. Therapeut., 2011, 90(1), 77-89.
49. Chen, H.C.; Farese, R.V. Turning WAT into BAT gets rid of fat. Nature Med., 2001, 7(10), 1102-1103.
50. Ahfeldt, T.; Schinzel, R.T.; Lee, Y.-K.; Hendrickson, D.; Kaplan, A.; Lum, D.H.; Camahort, R.; Xia, F. Shay, J.; Rhee, E.P.; Clish, C.B.; Deo, R.C.; Shen, T.; Lau, F.H.; Cowley, A.; Mowrer, G.; Al-Siddiqi, H.; Nahrendorf, M.; Musunuru, K.; Gerszten, R.E.; Rinn, J.L.; Cowan, C.A. Programming human pluripotent stem cells into white and brown adipocytes. Nature Cell Biol., 2012, 14(2), 209-219.
51. Whittle, A.J.; Lopez, M.; Vidal-Puig, A. Using brown adipose tissue to treat obesity - the central issue. Trends Mol. Med., 2011, 17(8), 405-411.
52. Tan, C.Y.; Ishikawa, K.; Virtue, S.; Vidal-Puig, A. Brown adipose tissue in the treatment of obesity and diabetes: Are we hot enough? J. Diab. Investig., 2011, 2(5), 341-350.
53. Rankinen, T.; Zuberi, A.; Chagnon, Y.C. The human obesity gene map: the 2005 update. Obesity, 2006, 14(4), 529-644.
54. Heal, D.J.; Gosden, J.; Smith, S.L. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol., 2009, 68(6), 861-874.
55. Niswender, K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diab. Obes. Metab., 2010, 12(4), 267-287.
56. Witkamp, R.F. Current and future drug targets in weight management. Pharm. Res., 2011, 28(8), 1792-1818.
57. Janssens, A.C.; Pardo, M.C.; Steyerberg, E.W.; van Dujin, CM. Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am. J. Hum. Genet, 2004, 74(3), 585-588.
58. Risch, N.; Merikangas, K. The future of genetic studies of complex human diseases. Science, 1996, 273(5281), 1516-1517.
59. Müller, G. Personalized prognosis and diagnosis of type II diabetes - vision or fiction? Pharmacology, 2010, 85(3), 168-187.
60. McCarthy, M.I. Growing evidence for diabetes susceptibility genes from genome scan data. Curr. Diab. Rep., 2003, 3(2), 159-167.
61. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365(9467), 1333-1346.
62. Lyssenko, V.; Almgren, P.; Anevski, D.; Orho-Melander, M.; Sjogren, M.; Saloranta, C. Genetic prediction of future type 2 diabetes. PLoS Med., 2005, 2(12), 1299-1307.
63. Florez, J.C.; Hirschhorn, J.N.; Altshuler, D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet, 2003, 4, 257-291.
64. McCarroll, S.A.; Altshuler, D.M. Copy-number variation and association studies of human disease. Nat. Genet, 2007, 39(7 Suppl.), S37-S42.
65. Jain, K.K. Nanodiagnostics: application of nanotechnology in molecular diagnostcs. Expert Rev. Mol. Diagn., 2003, 3(2), 153-161.
66. Jain, K.K. Proteomics: delivering new routes to drug discovery -Part 1. Drug Discov. Today, 2001, 6(15), 772-774.
67. Billingsley, M.L. Druggable targets and targeted drugs: Enhancing the development of new therapeutics. Pharmacology, 2008, 82(4), 239-244.
68. Jain, K.K. Proteomics: delivering new routes to drug discovery -Part 2. Drug Discov. Today, 2001, 6(16), 829-832.
69. Loos, R.J.F. Recent progress in the genetics of common obesity. Br. J. Clin. Pharmacol, 2009, 68(6), 811-829.
70. Field, B.C.; Chaudhri, O.B.; Bloom, S.R. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol, 2009, 68(6), 830-843.
71. Sargent, B.J.; Moore, N.A. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol, 2009, 68(6), 852-860.
72. Musri, M.M.; Carmona, M.C.; Hanzu, F.A.; Kaliman, P.; Gomis, R.; Parrizas, M. Histone demethylase LSD1 regulates adipogenesis. J. Biol. Chem., 2010, 285(39), 30034-30041.
73. Musri, M.M.; Gomis, R.; Parrizas, M. A chromatin perspective of adipogenesis. Organogenesis, 2010, 6(1), 15-23.
74. Kiskinis E.; Hallberg, M.; Christian, M.; Olofsson, M.; Dilworth, S.M.; White, R.; Parker, M.G. RIP140 directs histone and DNA methylation to silence Ucp1 expression in white adipocytes. EMBO J., 2007, 26(23), 4831-4840.
75. Musri, M.M.; Gomis, R.; Parrizas, M. Chromatin and chromatin-modifying proteins in adipogenesis. Biochem. Cell Biol, 2007, 85(4), 397-410.
76. Musri, M.M.; Corominola, H.; Casamitjana, R.; Gomis, R.; Parrizas, M. Histone H3 lysine 4 demethylation signals the transcriptional competence of the adiponectin promoter in preadipocytes. J. Biol. Chem., 2006, 281(25), 17180-17188.
77. Lee, J.; Saha, P.K.; Yang, Q.-H.; Lee, S.; Park, J.Y.; Suh, Y.; Lee S-K.; Chan, L. Roeder, R.G.; Lee, J.W. Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc. Natl. Acad. Sci. USA, 2008, 105(49), 19229-19234.
78. Tateishi, K.; Okada, Y.; Kallin, E.M.; Zhang, Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature, 2009, 458(7239), 757-761.
79. Cho, Y-W.; Hong, S.; Jin, Q.; Lee, J.-E.; Gavrilova, O.; Ge, K. Histone methylation regulator PTIP is required for PPARy and C/EBPa expression and adipogenesis. Cell Metab., 2009, 10(1), 27-39.
80. Park, S.W.; Huang, W.-H.; Persaud, S.D.; Wei, L.-N. RIP140 in thyroid hormone-repression and chromatin remodeling of Crabp1 gene during adipocyte differentiation. Nucl. Acids Res., 2009, 37(21), 7085-7094.
81. Heightman, T.D. Therapeutic prospects for epigenetic modulation. Expert. Opin. Ther. Targets, 2011, 15(6), 729-740.
82. Gallou-Kabani, C; Junien, C. Nutritional epigenomics of metabolic syndrome. New perspective against the epidemic. Diabetes, 2005, 54(7), 1899-1906.
83. Grundy, S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev. Drug Discov., 2006, 5(4), 295-309.
84. Zimmet, P.; Alberti, K.G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature, 2001, 414(6865), 782-787.
85. Braud, S.; Ciufolini, M.; Harosh, I. Energy expenditure genes or energy absorption genes: a new target for the treatment of obesity and type II diabetes. Future Med. Chem., 2010, 2(12), 1777-1783.
86. Hsu, Y.-W.; Chu, D.-C.; Ku, P.-W.; Liou, T.-H.; Chou, P. Pharma-cotherapy for obesity: Past, present and future. J. Exp. Clin. Med., 2010, 2(3), 118-123.
87. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: pathogenesis and treatment. Lancet, 2008, 371(9631), 2153-2156.
88. Hirshberg, B.; Raz, I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care, 2011, 34 (Suppl. 2), S101-S106.
89. Haffner, S.M.; Letho, S.; Rönnemaa, T.; Pyörälä, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339(4), 229-234.
90. Meier, M.; Hummel, M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag., 2009, 5, 859-871.
91. Frank, R.; Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov., 2003, 2(7), 566-580.
92. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D:; Fox, C.S.; Jacques, P.F.; Fernandez, C.; O'Donnell, C.J.; Carr, S.A., Mootha, V.K.; Florez, J.C.; Souza, A.; Melander, O.; Clish, C.B.; Gerszten, R.E. Metabolite profiles and the risk of developing diabetes. Nat. Med., 2011, 17(4), 448-453.
93. Wehling, M. Drug development in the light of translational science: shine or shade. Drug Discov. Today, 2011, 16(23/24), 1076-1083.
94. th January 2011].
95. Malandrino, N.; Smith, R.J. Personalized medicine in diabetes. Clin. Chem., 2011, 57(2), 231-240.
96. Yoneshiro, T.; Aita, S.; Matsushita, M.; Okamatsu-Ogura, Y.; Kameya, T.; Kawai, Y.; Miyagawa, M.; Tsujisaki, M.; Saito, M. Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity, 2011, 19(9), 1755-1760.
97. Cypess, A.M.; Kahn, C.R. The role and importance of brown adipose tissue in energy homeostasis. Curr. Opin. Pediatr., 2010, 22(4), 478-484.
98. Tseng, Y.-H.; Cypess, A.M.; Kahn, C.R. Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov., 2010, 9(6), 465-482.
99. Cypess, A.M. A new connection between muscle and brown fat. J. Pediatrics, 2011, 158(5), 696-698.
100. Müller, G.; Wied, S. The sulfonylurea drug, glimepiride, stimulates glucose transport, Glucose transporter translocation, and dephos-phorylation In insulin-resistant rat adipocytes in vitro. Diabetes, 1993, 42(12), 1852-1867.
101. Müller, G.; Hartz, D.; Pünter, J.; Ökonomopulos, R.; Kramer, W. Differential Interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor: I. Binding characteristics. Biochim. Biophys Acta, 1994. 1191(2), 267-277.
102. Kramer, W.; Müller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.-D. Differential interaction of glimepiride and glibenclamide with the ß-cell sulfonylurea receptor: II. Photoaffin-3 ity labeling of a 65-kDa protein with [H]glimepiride. Biochim. Biophys. Acta, 1994, 1191(2), 278-290.
103. Müller, G.; Dearey, A.E.; Korndörfer, A.; Bandlow, W. Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. J. Cell Biol., 1994, 126(5), 1267-1276.
104. Kramer, W.; Müller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.-D. The molecular interaction of sulfonylureas + with ß-cell ATP-sensitive K -channels. Diabetes Res. Clin. Pract., 1995, 28(Suppl.), S67-S80.
105. Müller, G.; Satoh, Y.; Geisen, K. Extrapancreatic effects of sulfon-ylureas - a comparison between glimepiride and conventional sul-fonylureas. Diabetes Res. Clin. Pract., 1995, 28(Suppl.), S115-S137.
106. Kramer, W.; Geisen, K.; Müller, G. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at pancreatic ß-cells. Horm. Metab. Res., 1996, 28(9), 464-468.
107. Müller, G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol. Med., 2000, 6(11), 907-933
108. Müller, G. The mode of action of glimepiride - Beyond insulin secretion. Curr. Med. Chem., 2005, 5, 499-518.
109. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Le-febre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, K.; Heine R.J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet, 2005, 366(9493), 1279-1289.
110. Sarafidis, P.A.; Bakris, G.L. Protection of the kidney by thia-zolidinediones: an assessment from bench to bedside. Kidney Int., 2006, 70(7), 1223-1233.
111. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; lavine, J.E.; Tonascia, J.; Unalp, A.; Van Natta, M.; Clark, J.; Brunt, E.M.; Kleiner, D.E.; Hoofnagle, J.H.; Robuck, P.R.; NASH CRN. Piogli-tazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362(18), 1675-1685.
112. Lecka-Czernik, B. Aleglitazar, a dual PPARalpha and PPAR-gamma agonist for the potential oral treatment of type 2 diabetes mellitus. Drugs, 2010, 13(11), 793-801.
113. Coll, T.; Rodriguez-Calvo, R.; Barroso, E.; Serrano, L.; Eyre, E.; Palomer, X.; Vazquez-Carrera, M. Peroxisome proliferator-activator receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr. Mol. Pharmacol., 2009, 2(1), 46-55.
114. Best, J.H.; Hoogwerf, B.J.; Herman, W.H.; Pelletier, E.M.; Smith, D.B.; Wenten, M.; Hussein, M.A. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide I (GLP-I) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care, 2011, 34(1), 90-95.
115. Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3(3), 153-165.
116. Hoerger, T.J.; Segel, J.E.; Gregg, E.W.; Saaddine, J.B. Is glycemic control improving in U.S. adults? Diabetes Care, 2008, 31(1), 81-86.
117. Moller, D.E. Metabolic disease drug discovery.- "Hitting the target" is easier said than done. Cell Metabol., 2012, 15(1), 19-24.
118. American Diabetes Association. Standards of medical care in dia-betes-2011. Diabetes Care, 2011, 34(Suppl. 1), S11-S61.
119. th January 2011].
120. Hermanowski-Vosatka, A.; Balkovec, J.M.; Cheng, K.; Chen, H.Y.; Hernandez, M.; Koo, G.C.; Le Grand, C.B.; Li, Z.; Metzger, J.M.; Mundt, S.S.; Noonan, H.; Nunes, C.N., Olson, S.H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J.M.; Shah, K.; Springer, M.S.; Strack, A.M.; Strowski, M.; Wu, T.; Xiao, J.; Zhang, B.B.; Wright, S.D.; Thieringer, R. 11beta-HSDI inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med., 2005, 202(4), 517-527.
121. Rosenstock, J.; Banarer, S.; Fonseca, V.A:; Inzucchi, S.E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W.V.; Seckl, J.R.; Huber, R.; INCB13739-202 Principal Investigators. The II beta-hydroxysteroid dehydrogenase type I inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care, 2010, 33(7), 1516-1522.
122. Feig, P.U.; Shah, S.; Hermanowski-Vosatka, A.; Plotkin, D.; Springer, M.S.; Donahue, S.; Thach, C.; Klein, E.J.; Lai, E.; Kaufman, K.D. Effects of an IIbeta-hydroxysteroid dehydrogenase type I inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes. Metab., 2011, 13(6), 498-504.
123. Chu, Z.L.; Jones, R.M.; He, H.; Carroll, C.; Gutierez, V.; Lucman, A.; Moloney, M.; Gao, H.; Mondala, H.; Bagnol, D.; Unett, D.; Liang, Y.; Demarest, K.; Semple, G.; Behan, D.P.; Leonhard, J. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology, 2007, 148(6), 2601-2609.
124. Semple, G.; Ren, A.; Fioravanti, B.; Pereira, G.; Calderon, I.; Choi, K.; Xiong, Y.; Shin, Y.J.; Gharbaoui, T.; Sage, C.R.; Morgan, M.; Xing, C.; Chu, Z.L.; Leonhard, J.N.; Grottick, A.J.; Al-Shamma, H.; Liang, Y.; Demarest, K.T. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg. Med. Chem. Lett., 2011, 21(10), 3134-3141.
125. Overton, H.A.; Babbs, A.J.; Doel, S.M.; Fyfe, M.C.; Gardner, L.S.; Griffin, G.; Jackson, H.C.; Procter, M.J.; Rasamison, C.M.; Tang-Christensen, M.; Widdowson, P.S.; Williams, G.M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethano-lamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab., 2006, 3(3), 167-175.
126. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glu-cagon-like peptide I secretion through TGR5 in a murine enteroen-docrine cell line STC-I. Biochem. Biophys. Res. Commun., 2005, 329(1), 386-390.
127. Watanabe, M.; Houten, S.M.; Mataki, C.; Christoffolete, M.A.; Kim, B.W.; Sato, H.; Messaddeq, N.; Harney, J.W.; Ezaki, O.; Ko-dama, T.; Schoonjans, K.; Bianco, A.C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 2006, 439(7075), 484-489.
128. Keitel, V.; Donner, M.; Winandy, S.; Kubitz, R.; Häussinger, D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun., 2008, 372(1), 78-84.
129. Keitel, V.; Reinehr, R.; Gatsios, P.; Rupprecht, C.; Görg, B.; Sel-bach, B.; Häussinger, D.; Kubitz, R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology, 2007, 45(3), 695-704.
130. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; Pellicciiari, M.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab., 2009, 10(3), 167-177.
131. Chen, X.; Lou, G.; Meng, Z.; Huang, W. TGR5: A novel target for weight maintenance and glucose metabolism. Exper. Diab. Res., 2011, 2011:853501, doi:10.11557/2011/853501.
132. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medve-dik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRTI as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450(7170), 712-716.
133. Zhang, Q.J.; Wang, Z.; Chen, H.Z.; Zhou, S.; Zheng, W.; Liu, G.; Wei, Y.S.; Cai, H.; Liu, D.P.; Liang, C.C. Endothelium-specific overexpression of class III deacetylase SIRTI decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res., 2008, 80(2), 191-199.
134. Hsu, C.P.; Zhai, P.; Yamamoto, T.; Maejima, S.; Matsushima, S.; Hariharan, N.; Shao, D.; Takagi, H.; Oka, S.; Sadoshima, J. Silent information regulator I protects the heart from ische-mia/reperfusion. Circulation, 2010, 122(21), 2170-2182.
135. Li, L.; Zhang, H.N.; Chen, H.Z.; Gao, P.; Zhu, L.H.; Li, H.L.; Lv, X.; Zhang, Q.J.; Zhang, R.; Wang, Z.; She, Z.G.; Zhang, R.; Wei, Y.S.; Du, G.H.; Liu, D.P.; Liang, C.C. SIRTI acts as a modulator of neointima formation following vascular injury in mice. Circ. Res., 2011, 108(10), 1180-1189.
136. Komoroski, B.; Vachharajani, N.; Feng, Y.; Li, L.; Kornhauser, D.; Pfister, M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther., 2009, 85(5), 513-519.
137. Aires, I.; Calado, J. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus. Curr. Opin. Investig. Drugs, 2010, 11(10), 1182-1190.
138. Vemula, S.; Roder, K.E.; Yang, T.; Bhat, G.J.; Thekkumkara, T.J.; Abbruscato, T.J. A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J. Pharmacol. Exp. Ther., 2009, 328(2), 487-495.
139. Edfalk, S.; Steneberg, P.; Edlund, H. Gpr40 is expressed in en-teroendocrine cells and mediates free fatty acid stimulation of in-cretin secretion. Diabetes, 2008, 57(9), 2280-2287.
140. Nagasumi, K.; Esaki, R.; Iwachidow, K.; Yasuhara, Y.; Ogi, K.; Tanaka, H.; Nakata, M.; Yano, T.; Shimakawa, K.; Taketomi, S.; Takeuchi, K.; Odaka, H.; Kaisho, Y. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes, 2009, 58(5), 1067-1076.
141. Tan, C.P.; Feng, Y.; Zhou, Y.P.; Eiermann, G.J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T.E.; Einstein, M.; Kumar, S.; Berger, J.P.; Mills, S.G.; Thornberry, N.A.; Yang, L.; Howard, A.D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes, 2008, 57(8), 2211-2219.
142. Zhang, X.; Yan, G.; Li, Y.; Zhu, W.; Wang, H. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed. Pharmacother., 2010, 64(9), 647-651.
143. Emilsson, V.; Thorleifsson, G.; Zhang, B.; Leonardson, A.S.; Zink, F.; Zhu, J. Genetics of gene expression and its effect on disease. Nature, 2008, 27(7186), 423-428.
144. Guido, N.J.; Wang, X.; Adalsteinsson, D.; McMillen, D.; Hasty, J.; Cantor, C.R.A.; Elston, T.C.; Collins, J.J. A bottom-up approach to gene regulation. Nature, 2006, 439(7078), 856-860.
145. Bogardus, C. Missing heritability and GWAS utility. Obesity, 2009, 17(2), 209-210.
146. Brommage, R.; Desai, U.; Revelli, J.P.; Donoviel, D.B.; Fontenot, G.K.; Dacosta, C.M.; Smith, D.D.; Kirkpatrick, K.J.; Coker, K.J.; Donoviel, M.S.; Eberhart, D.E.; Holt, K.H.; Kelly, M.R.; Paradee, W.J.; Philips, A.V.; Platt, K.A.; Suwanichkul, A.; Hansen, G.M.; Sand, A.T.; Zambrowicz, B.P.; Powell, D.R. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity, 2008, 16(10), 2362-2367.
147. Li, M.; Cheung, B.M.Y. Pharmacotherapy for obesity. Br. J. Clin. Pharmacol., 2009, 68(6), 804-810.
148. McCarthy, M.I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med., 2010, 363(24), 2339-2350.
149. Sladek, R.; Rocheleau, G.; Rung, J.; Dina, C.; Shen, L.; Serre, D.; Boutin, P.; Vincent, D.; Belisle, A.; Hadjadj, S.; Balkau, B.; Heude, B.; Charpentier, G.; Hudson, T.J.; Montpetit, A.; Pshezhetsky, A.V.; Prentki, M.; Posner, B.I.; Balding, D.J.; Meyre, D.; Poly-chronakos, C.; Frrroguel, P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, 445(7130), 881-885.
150. Scott, L.J.; Mohlke, K.L.; Bonnycastle, L.L.; Bonnycastle, L.L.; Willer, C.J.; Li, Y.; Duren, W.L.; Erdos, M.R.; Stringham, H.M.; Chines, P.S.; Jackson, A.U.; Ding, C.J.; Swift, A.J.; Narisu, N.; Hu, T.; Pruim, R.; Xiao, R.; Li, X.Y.; Conneely, K.N.; Riebow, N.L.; Spau, A.G.; Tong, M.; White, P.P.; Hetrick, K.N.; Barnhart, M.W.; Bark, C.W.; Goldstein, J.L.; Watkins, L.; Xiang, F.; Saramies, J.; Buchanan, T.A.; Watanabe, R.M.; Valle, T.T.; Kinnunen, L.; Abe-casis, G.R.; Pugh, E.W.; Doheny, K.F.; Bergman, R.N.; Tuomile-tho, J.; Collins, F.S.; Boehnke, M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007, 316(5829), 1341-1345.
151. Zeggini, E.; Weedon, M.N.; Lindgren, C.M.; Frayling, T.M.; Elliott, K.S.; Lango, H.; Timpson, N.J.; Perry, J.R.; Rayner, N.W.; Freathy, R.M.; Barrett, J.C.; Shields, B.; Morris, A.P.; Ellard, S.; Groves, C.J.; Harries, L.W.; Marchini, J.L.; Owen, K.R.; Knight, B.; Cardon, L.R.; Walker, M.; Hitman, G.A.; Morris, A.D.; Doney, A.S.; Wellcome Trust Case Control Consortium (WTCCC), McCarthy, M.I.; Hattersley, A.T. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science, 2007, 316(5829), 1336-1341.
152. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447(7130), 661-678.
153. Zeggini, E.; Scott, L.J.; Saxena, R.; Voight, B.F.; Marchini, J.L.; Hu, T.; de Bakker, P.I.; Abecasis, G.R.; Almgren, P.; Andersen, G.; Ardlie, K.; Boström, K.B.; Bergman, R.N.; Bonnycastle, L.L.; Borch-Johnsen, K.; Burtt, N.P.; Chen, H.; Chines, P.S.; Daly, M.J.; Deodhar, P.; Ding, C.J.; Doney, A.S.; Duren, W.L.; Elliott, K.S. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet., 2008, 40(5), 638-645.
154. Dupuis, J.; Langenberg, C.; Prokopenko, I.; Saxena, R.; Soranzo, N.; Jackson, A.U.; Wheeler, E.; Glazer, N.L.; Bouatia-Naji, N.; Gloyn, A.L.; Lindgren, C.M.; Mägi, R.; Morris, A.P.; Randall, J.; Johnson, T.; Elliott, P.; Rybin, D.; Thorleifsson, G.; Henneman, P.; Grallert, H.; Dehghan, A.; Hottenga, J.J.; Franklin, C.S.; Navarro, P.; Song, K.; Goel, A.; Perry, J.R.; Egan, J.M.; Lajunen, T.; Gra-rup, N.; Doney, A.; Voight, B.F.; Stringham, H.M.; Li, M.; Kanoni, S.; Shrader, P.; Kumari, M. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet., 2010, 42(2), 105-116.
155. Friedman, J.M. Obesity: causes and control of excess body fat. Nature, 2009, 459(7245), 340-342.
156. Florez, J.C. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia, 2008, 51(7), 1100-1110.
157. Hattersley, A.T.; McCarthy, M.I. What makes a good genetic association study? Lancet, 2005, 366(9493), 1315-1323.
158. Lango, H. UK type 2 diabetes genetics consortium, Palmer, C.N.; Palmer, C.N.; Morris, A.D.; Zeggini, E.; Hattersley, A.T.; McCarthy, M.I.; Frayling, T.M.; Weedon, M.N. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes, 2008, 57(11), 3129-3135.
159. van Hoek, M.; Dehghan, A.; Witteman, J.C.; van Duijn, C.M.; Uitterlinden, A.G.; Oostra, B.A.; Hofman, A.; Sijbrands, E.J.; Jans-sens, A.C. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes, 2008, 57(11), 3122-3128.
160. Feero, W.G.; Guttmacher, A.; Collins, F.S. Genomic medicine-an updated primer. New Engl. J. Med., 2010, 362, (21), 2001-2011.
161. Thorleifsson, G.; Walters, G.B.; Gudbjartsson, D.F.; Steinthorsdot-tir, V.; Sulem, P.; Helgadottir, A.; Styrkarsdottir, U.; Gretarsdottir, S.; Thorlacius, S.; Jonsdottir, I.; Jonsdottir, T.; Olafsdottir, E.J.; Olafsdottir, G.H.; Jonsson, T.; Jonsson, F.; Hansen, T.; Andersen, G.; Jorgensen, T.; Lauritzen T.; Aben, K.K.; Verbeek, A.L.; Roeleveld, N.; Kampman, E.; Yanek, L.R.; Becker, L.C.; Rafnar, T.; Becker, D.M.; Gulcher, J.; Kiemeney, L.A.; Pedersen, O.; Kong, A.; Thorsteinsdottir, U.; Stefansson, K. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet., 2009, 41(1), 18-24.
162. Loos R.J.F.; Bouchard, C. FTO: the first gene contributing to common forms of human obesity. Obesity Rev., 2008, 9(3), 246-250.
163. Han, Z.; Niu, T.; Chang, J.; Lei, X.; Zhao, M.; Wang, Q.; Cheng, W.; Wang, J.; Feng, Y.; Chai, J. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature, 2010, 464(7292), 1205-1209.
164. Haslam, D.W.; James, W.P. Obesity. Lancet, 2006, 366(9492), 1197-1209.
165. Larder, R.; Cheung, M.K.M.; Tung, Y.C.L.; Yeo, G.S.H.; Coll, A.P. Where to go with FTO. Trends Endocrinol. Metab., 2011, 22(2), 53-59.
166. Church, C.; Moir, L.; McMurray, F.; Girard, C.; Banks, G.T.; Te-boul, L.; Wells, S.; Brüning, J.C.; Nolan, P.M.; Ashcroft, F.M.; Cox, R.D. Overexpression of Fto leads to increased food intake and results in obesity. Nature Genet., 2010, 42(12), 1086-1092.
167. Fischer, J.; Koch, L.; Emmerling, C. Inactivation of the FTO gene protects from obesity. Nature, 2009, 458(7240), 894-898.
168. Fawcett, K.A.; Barroso, I. The genetics of obesity: FTO leads the way. Trends Genet., 2010, 26(6), 266-274.
169. Stratigopoulos, G.; Leibel, R.L. FTO gains function. Nature Genet., 2010, 42(12), 1038-1039.
170. Wareham, N.J.; Franks, P.W.; Harding, A.H. Establishing the role of gene-environment interactions in the etiology of type 2 diabetes. Endocrinol. Metab. Clin. North Am., 2002, 31(3), 553-566.
171. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372(6505), 425-432.
172. Tartaglia, L.A.; Dembski, M.; Weng, X.; Deng, N.; Culpepper, J.; Devos, R.; Richards, G.J.; Campfield, L.A.; Clark, F.T.; Deeds, J.; Muir, C.; Sanker, S.; Moriarty, A.; Moore, K.J.; Smutko, J.S.; Mays, G.G.; Wool, E.A., Monroe, C.A., Tepper, R.I. Identification and expression cloning of a leptin receptor, OB-R. Cell, 1995, 83(7), 1263-1271.
173. Mihaescu, R.; van Hoek, K.; Sijbrands, E.J.; Uitterlinden, A.G.; Witteman, J.C.; Hofman, A.; van Duijn, C.M.; Janssens, A.C. Evaluation of risk prediction updates from commercial genome-wide scans. Genet. Med., 2009, 11(8), 588-594.
174. Timpson, N.J.; Lindgren, C.M.; Weedon, M.N.; Randall, J.; Ouwe-hand, W.H.; Strachan, D.P.; Rayner, N.W.; Walker, M.; Hitman, G.A.; Doney, A.S.; Palmer, C.N.; Morris, A.D.; Hattersley, A.T.; Zeggini, E.; Frayling, T.M.; McCarthy, M.I. Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. Diabetes, 2009, 58(2), 505-510.
175. Pearson, E.R. Pharmacogenetics in diabetes. Curr. Diab. Rep., 2009, 9(2), 172-181.
176. Kaplan, L.M. Pharmacological therapies for obesity. Gastroenterol. Clin. North. Am., 2005, 34(1), 91-104.
177. Pearson, E.R.; Starkey, B.J.; Powell, R.J.; Gribble, F.M.; Clark, P.M.; Hattersley, A.T. Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet, 2003, 362(9392), 1275-1281.
178. Winckler, W.; Burtt, N.P.; Holmkvist, J.; Cervin, C.; de Bakker, P.I.; Sun, M.; Almgren, P.; Tuomi, T.; Gaudet, D.; Hudson, T.J.; Ardlie, K.G.; Daly, M.J.; Hirschhorn, J.N.; Altshuler, D.; Groop, L. Association of common variation in the HNFIalpha gene region with risk of type 2 diabetes. Diabetes, 2005, 54(8), 2336-2342.
179. Flier, J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell, 2004, 116(2), 337-350.
180. Kaplan, O.I.; Doroquez, D.B.; Cevik, S.; Bowle, R.V.; Clarke, L.; Sanders, A.A.W.M.; Kida, K.; Rappoport, J.Z.; Sengupta, P.; Blac-que, O.E. Endoctyosis genes facilitate protein and membrane transport in C. elegans sensory cilia. Curr. Biol., 2012, 22(Feb. 12), 1-10.
181. Rosenbaum, J.L.; Witman, G.B. Intraflagellar transport. Nature Rev. Mol. Cell Biol., 2002, 3(11), 813-825.
182. Mykytyn, K.; Nishimura, D.Y.; Searby, C.C.; Shastri, M.; Yen, H.-j.; Beck, J.S.; Braun, T.; Streb, L.M.; Cornier, L.M.; Cox, G.F.; Fulton, A.B.; Carmi, R.; Lüleci, G.; Chandrasekharappa, S.C.; Collins, F.S.; Jacobson, S.G.; Heckenlively, J.R.; Weleber, R.G.; Stone, E.M.; Sheffield, V.C. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nature Genet., 2002, 31(4), 435-438.
183. Sheffield, V.C. Use of isolated populations in the study of a human obesity syndrome, the Bardet-Biedl syndrome. Pediatr. Res., 2004, 55(6), 908-911.
184. Rahmouni, K.; Fath, M.A.; Seo, S.; Thedens, D.R.; Berry, C.J.; Weiss, R.; Nishimura, D.Y.; Sheffield, V.C. Leptin resistance contributes to obesity and hypertension in mouse models of Bardet-Biedl syndrome. J. Clin. Invest., 2008, 118(4), 1458-1467.
185. Blacque, O.E.; Leroux, M.R. Human genome & diesease: Review, Bardet-Biedl syndrome: an emerging pathomechanism of intracel-lular transport. Cell. Mol. Life Sci., 2006, 63(18), 2145-2161.
186. Zaghloul, N.A.; Katsanis, N. Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy. J. Clin. Invest., 2009, 119(3), 428-437.
187. Guo, D.-F.; Rahmouni, K. Molecular basis of the obesity associated with Bardet-Biedl syndrome. Trends Endocrinol. Metabol., 2011, 22(7), 286-293.
188. ACCORD Study Group; ACCORD Eye Study Group; Chew, E.Y.; Ambrosius, W.T.; Davis, M.D.; Danis, R.P.; Gangaputra, S.; Gre-ven, C.M.; Hubbard, L.; Esser, B.A.; Lovato, J.F.; Perdue, L.H.; Goff, D.C.Jr.; Cushman, W.C.; Ginsberg, H.N.; Elam, M.B.; Genuth, S.; Gerstein, H.C.; Schubart, U.; Fine, L.J. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med., 2010, 363(3), 233-244.
189. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesäniemi, Y.A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366(9500), 1849-1861.
190. Tharakan, G.; Tan, T.; Bloom, S. Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci., 2011, 32(1), 8-15.
191. Thaler, J.P.; Schwartz, M.W. Minireview: Inflammation and obesity pathogenesis: The hypothalamus heats up. Endocrinology, 2010, 151(9), 4109-4115.
192. Mantzoros, C.S.; Magkos, F.; Brinkoetter, M.; Sienkiewicz, E.; Dardeno, T.A.; Kim, S.-Y., Hamnvik, O.-P.R.; Koniaris, A. Leptin in human physiology and pathophysiology. Am. J. Physiol. Endo-crinol. Metab., 2011, 301(4), E567-E584.
193. O'Rahilly, S. Human genetics illuminates the paths to metabolic disease. Nature, 2009, 462(7271), 307-314.
194. Askari, H.; Tykodi, G.; Liu, J.; Dagago-Jack, S. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. J. Clin. Endocrinol. Metab., 2010, 95(8), 3836-3843.
195. Deng, Y.; Scherer, P.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N.Y. Acad. Sci., 2010, 1212(Nov.), E1-E19.
196. Hansen, D.; Densale, P.; Beelen, M.; Jonkers, R.A.; Mullens, A.; Corluy, L.; Meeusen, R.; van Loon, L.J. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur. J. Appl. Physiol., 2010, 109(3), 397-404.
197. Sell, H.; Divoux, A.; Poitou, C.; Basdevant, A.; Bouillot, J.L.; Bedossa, P.; Tordjman, J.; Eckel, J.; Clement, K. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin. Endocrinol. Metab., 2010, 95(6), 2892-2896.
198. Tönjes, A.; Fasshauer, M.; Kratzsch, J.; Stumvoll, M.; Blüher, M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE, 2010, 5(11), e13911.
199. Klöting, N.; Fassahuer, M.; Dietrich, A.; Kovacs, P.; Schön, M.R.; Kern, M.; Stumvoll, M.; Blüher, M. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab., 2010, 299(3), E506-E515.
200. Chakaroun, R.; Raschpichler, M.; Klöting, N.; Oberbach, A.; Flehmig, G.; Kern, M.; Schon, M.R.; Shang, E.; Lohmann, T.; Dressler, M. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism, 2011, doi:org/10.1016/j.metabol.2011.10008.
201. Ruige, J.B.; Mertens I.L.; Bartholomeeusen, E.; Dirinck, E.; Fer-rannini, E.; Van Gaal, L.F. Fasting-based estimates of insulin sensitivity in overweight and obesity: a critical appraisal. Obesity, 2006, 14(7), 1250-1256.
202. Lapauw, B.; Ouwens, M.; t'Hart, L.M.; Wuyts, B.; Holst, J.J.; T'Sjoen, G.; Kaufman, J.M.; Ruige, J.B. Sex steroids affect triglyc-eride handling, glucose-dependent insulinotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men. Diabetes Care, 2010, 33(8), 1831-1833.
203. Shoelson, S.; Lee, J.; Goldfine, A. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116(7), 1793-1801.
204. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature, 2006, 444(7121), 860-867.
205. Caspar-Bauguil, S.; Cousin, B.; Galinier, A.; Segafredo, C.; Nib-belink, M.; Andre, M.; Casteilla, L.; Penicaud, L. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett., 2005, 579(17), 3487-3492.
206. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.Q.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell, 2010, 142(5), 687-698.
207. Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; Cho-quet, H.; Besnard, P.; Lecoeur, C.; Vivequin, S.; Ayukawa, K.; Takeuchi, M.; Ozawa, K.; Tauber, M.; Maffeis, C.; Morandi, A.; Buzzetti, R.; Elliott, P.; Pouta, A.; Jarvelin, M.R.; Körner, A.; Ki-ess, W.; Pigeyre, M.; Caiazzo, R.; Van Hul, W.; Van Gaal, L.; Horber, F.; Balkau, B.; Levy-Marchal, C.; Rouskas, K.; Kouvatsi, A.; Hebebrand, J.; Hinney, A.; Scherag, A.; Pattou, F.; Meyre, D.; Koshimizu, T.A.; Wolowczuk, I.; Tsujimoto, G.; Froguel, P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature, 2012, doi:10.1038/nature10798.
208. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Med., 2005, 11(1), 90-94.
209. Hoehn, K.L.; Salmon, A.B.; Hohnen-Behrens, C.; Turner, N.; Hoy, A.J.; Maghzal, G.J.; Stocker, R.; Van Remmen, H.; Kraegen, E.W.; Cooney, G.J.; Richardson, A.R.; James, D.E. Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. USA, 2009, 106(42), 177787-17792.
210. Benito, M. Tissue-specificity of insulin action and resistance. Arch. Physiol. Biochem., 2011, 117(3), 96-104.
211. Pickup, J.C.; Crook, M.A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia, 1998, 41(10), 1241-1248.
212. Bournat, J.C.; Brown, C.W. Mitochondrial dysfunction in obesity. Curr. Opin. Endocrinol. Diabetes Obes., 2010, 17(5), 446-452.
213. Kahn, C.R. Diabetes. Causes of insulin resistance. Nature, 1995, 373(6513), 384-385.
214. Weisberg, S.P.; McCann, D.; Desai, M. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 2003, 112(12), 1796-1808.
215. Biddinger, S.B.; Kahn, C.R. From mice to men: Insights into the insulin resistance syndromes. Annu. Rev. Physiol., 2006, 68. 123-158.
216. Kadowaki, T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest., 2000, 106(4), 459-465.
217. Cowherd, R.M.; Lyle, R.E.; McGehee, R.E.Jr. Molecular regulation of adipocyte differentiation. Semin. Cell Dev. Biol., 1999, 10(1), 3-10.
218. Ogawa, R.; Tanaka, C.; Sato, M.; Nagasaki, H.; Sugimura, K.; Okumura, K.; Nakagawa, Y.; Aoki, N. Adipocyte-derived microve-sicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem. Biophys. Res. Com-mun., 2010, 398(4), 723-729.
219. Aoki, N.; Jin-no, S.; Nakagawa, Y.; Asai, N.; Arakawa, E.; Ta-mura, N.; Tamura, T.; Matsuda, T. Identification and characterization of microvesicles secreted by 3T3-L1 adipocytes: Redox- and hormone-dependent induction of milk fat globule-epidermal growth factor 8-associated microvesicles. Endocrinology, 2007, 148(8), 3850-3862.
220. Clapham, J.C.; Arch, J.R. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes. Metab., 2007, 9(3), 259-275.
221. Cannon, B.; Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev., 2004, 84(1), 277-359.
222. Cypess, A.M.; Kahn, C.R. Brown fat as a therapy for obesity and diabetes. Curr. Opin. Endocrinol. Diabet. Obes., 2010, 17(2), 143-149.
223. Vernochet, C.; McDonald, M.E.; Farmer, S.R. Brown adipose tissue: A promising target to combat obesity. Drug News Perspect., 2010, 23(7), 409-417.
224. Badman, M.K.; Flier, J.S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology, 2007, 132(6), 2103-2115.
225. Klein, J.; Fasshauer, M.; Klein, H.H.; Benito, M.; Kahn, C.R. Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. BioEs-says, 2002, 24(4), 382-388.
226. Kajimura, S.; Seale, P.; Spiegelman, B.M. Transcriptional control of brown fat development. Cell Metabol., 2010, 11(4), 257-262.
227. Frontini, A.; Cinti, S. Distribution and development of brown adi-pocytes in the murine and human adipose organ. Cell Metab., 2010, 11(4), 253-256.
228. Vila-Bedmer, R.; Fernandez-Veledo, S. A new era for brown adipose tissue: New insights into brown adipocyte function and differentiation. Arch. Physiol. Biochem., 2011, 117(3), 195-208.
229. Arner, P.; Bernard, S.; Salehpour, M.; Possnert, G.; Liebl, J.; Steier, P.; Buchholz, B.A.; Eriksson, M.; Arner, E.; Hauner, H.; Skurk, T.; Ryden, M.; Frayn, K.N.; Spalding, K.L. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature, 2011, 478(7367), 110-113.
230. Cinti, S. Between brown and white: Novel aspects of adipocyte differentiation. Annals Med., 2011, 43(2), 104-115.
231. Kohn, B. Does functional brown adipose tissue play an integral role in pediatric energy balance and metabolism. J. Pediatrics, 2011, 159(6), 939-944.
232. Ootsuka, Y.; Kulasekara, K.; de Menezes, R.C.; Blessing, W.W. SR59230A, a beta-3 adrenoceptor antagonist, inhibits ultradian brown adipose tissue thermogenesis and interrupts associated episodic brain and body heating. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 301(4), R987-R994.
233. Jimenez-Preitner, M.; Berney, X.; Uldry, M.; Vitali, A.; Cinti, S.; Ledford, J.G.; Thorens, B. Plac8 is an inducer of C/EBPß required for brown fat differentiation, thermoregulation, and control of body weight. Cell Metab., 2011, 14(5), 658-670.
234. Cinti, S. Transdifferentiation properties of adipocytes in the adipose organ. Am. J. Physiol. Endocrinol. Metab., 2009, 927(5), E977-E986.
235. Cinti, S. The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 73(1), 9-15.
236. Barbatelli, G.; Murano, I.; Madsen, L.; Hao, Q.; Jimenez, M.; Kris-tiansen, K.; Giacobino, J.P.; De Matteis, R.; Cinti, S. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdif-ferentiation. Am. J. Physiol. Endocrinol. Metab., 2010, 298(6), E1244-1253.
237. Tran, K.-V.; Gealekman, O.; Frontini, A.; Zingaretti, M.C.; Morro-ni, M.; Giordano, A.; Smorlesi, A.; Perugini, J.; De Matteis, R.; Sbarbati, A.; Corvera, S.; Cinti, S. The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. Cell Metab., 2012, 15(2), 222-229.
238. Cristancho, A.G.; Lazar, M.A. Forming functional fat: a growing understanding of adipocyte differentiation. Nature Rev., 2011, 12(11), 722-734.
239. Forner, F.; Kumar, C; Luber, C.A.; Fromme, T.; Klingenspor, M.; Mann, M. Proteome differences between brown and white fat mitochondria reveal specialized metabolic functions. Cell Metab., 2009, 10(4), 324-335.
240. Seale, P.; Conroe, H.M.; Estall, J.; Kajimura, S.; Frontini, A.; Ishi-bashi, J.; Cohen, P.; Cinti, S.; Spiegelman, B.M. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J. Clin. Invest., 2011, 121(1), 96-105.
241. Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Boström, E.A.; Choi, J.H.; Long, J.Z.; Kajimura, S.; Zingaretti, M.C.; Vind, B.F.; Tu, H.; Cinti, S.; Hojlund, K.; Gygi, S.P.; Spiegelman, B.M. A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and ther-mogenesis. Nature, 2012, 481(7382), 463-468.
242. Patwari, P.; Emilsson, V.; Schadt, E.E.; Chutkow, W.A.; Lee, S.; Marsili, A.; Zhang, Y.; Dobrin, R.; Cohen, D.E.; Larsen, P.R.; Zavacki, A.M.; Fong, L.G.; Young, S.G.; Lee, R.T. The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab., 2011, 14(5), 671-683.
243. Zhang, C; McFarlane, C; Lokireddy, S.; Masuda, S.; Ge, X.; Gluckman, P.D.; Sharma, M.; Kambadur, R. Inhibition of my-ostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Dia-betologia, 2012, 55(1), 183-193.
244. de Gassart, A.; Geminard, C; Fevrier, B.; Raposo, G.; Vidal, M. Lipid raft-associated protein sorting in exosomes. Blood, 2003, 102(13), 4336-4344.
245. Del Conde, I.; Shrimpton, C.N.; Thiagarajan, P.; Lopez, J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood, 2005, 106(5), 1604-1611.
246. Scott, R.E.; Perkins, R.G.; Zschunke, M.A.; Hoerl, B.J.; Maerck-lein, P.B. Plasma membrane vesiculation in 3T3 and SV3T3 cells. J. Cell Sci., 1979, 35(Feb.), 229-243.
247. Heijnen, H.F.; Schiel, A.E.; Fijnheer, R.; Geuze, H.J.; Sixma, J.J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocy-tosis of multivesicular bodies and alpha-granules. Blood, 1999, 94(11), 3791-3799.
248. Piccin, A.; Murphy, W.G.; Smith, O.P. Circulating microparticles: pathophysiology and clinical implications. Blood Rev., 2007, 21(3), 157-171.
249. Denzer, K.; Kleijmeer, M.J.; Heijnen, H.F.; Stoorvogel, W.; Geuze, H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci., 2000, 113(Pt19), 3365-3374.
250. Müller, G.; Schneider, M.; Biemer-Daub, G.; Wied, S. Microvesicles released from rat adipocytes and harboring glycosylphosphati-dylinositol-anchored proteins transfer RNA stimulating lipid synthesis. Cell. Signal., 2011, 23(7), 1207-1223.
251. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles: artefacts no more. Trends Cell Biol, 2009, 19(2), 43-51.
252. Aliotta, J.M.; Pereira, M.; Johnson, K.W.; de Paz, N.; Dooner, M.S.; Puente, N.; Ayala, C; Brilliant, K.; Berz, D.; Lee, D.; Ram-ratnam, B.; McMillan, P.N.; Hixson, D.C.; Josic, D.; Quesenberry, P.J. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Experiment. Hematol, 2010, 38(3), 233-245.
253. Hata, T.; Murakami, K.; Nakatani, H.; Yamamoto, Y.; Matsuda, T.; Aoki, N. Isolation of bovine milk-derived microvesicles carrying mRNAs and microRNAs. Biochem. Biophys. Res. Commun., 2010, 396(2), 528-533.
254. Al-Nedawi, K.; Meehan, B.; Micallef, J.; Lhotak, V.; May, L.; Guha, A.; Rak, J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biol., 2008, 10(5), 619-624.
255. Pap, E.; Pallinger, E.; Pasztoi, M.; Falus, A. Highlights of a new type of intercellular communication: microvesicle-based information transfer. Inflamm. Res., 2009, 58(1), 1-8.
256. Müller, G.; Jung, C.; Straub, J.; Wied, S.; Kramer, W. Induced release of membrane vesicles from rat adipocytes containing glyco-sylphosphatidylinositol-anchored microdomain and lipid droplet signalling proteins. Cell. Signal., 2009, 21(2), 324-338.
257. Müller, G.; Jung, C.; Wied, S.; Biemer-Daub, G. Induced transloca-tion of glycosylphosphatidylinositol-anchored proteins from lipid droplets to adiposomes in rat adipocytes. Br. J. Pharmacol., 2009, 158(3), 749-770.
258. Müller, G.; Wied, S.; Straub, J.; Jung, C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur. J. Pharmacol., 2008, 597(1-3), 6-18.
259. Aoki, N.; Yokoyama, R.; Asai, N.; Ohki, M.; Ohki, Y.; Kusubata, K.; Heissig, B.; Hattori, K.; Nakagawa, Y.; Matsuda, T. Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis in vivo and in vitro. Endocrinology, 2010, 151(6), 2567-2576.
260. Müller, G.; Wied, S.; Jung, C.; Biemer-Daub, G.; Frick, W. Transfer of glycosylphosphatidylinositol-anchored 5'-nucleotidase CD73 from adiposomes into rat adipocytes stimulates lipid synthesis. Br. J. Pharmacol., 2010, 160(4), 878-891.
261. Müller, G.; Wied, S.; Jung, C.; Frick, W.; Biemer-Daub, G. Inhibition of lipolysis by adiposomes containing glycosylphosphatidyli-nositol-anchored Gce1 protein in rat adipocytes. Arch. Physiol. Biochem., 2010, 116(1), 28-41.
262. Spiegel, K.; Tasali, E.; Leproult, R.; van Cauter, E. Effects of poor sleep on glucose metabolism and obesity risk. Nat. Rev. Endocri-nol., 2009, 5(5), 253-261.
263. Bass, J.; Takahashi, J.S. Circadian integration of metabolism and energetics. Science, 2010, 330(6009), 1349-1354.
264. Duez, H.; Staels, B. Nuclear receptors linking circadian rhythms and cardiometabolic control. Arterioscler. Thromb. Vasc. Biol., 2010, 30(8), 1529-1534.
265. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; Mende, D.R.; Li, J.; Xu, J.; Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, H.; Zheng, H.; Xie, Y.; Tap, J.; Lepage, P.; Bertala, M.; Batto, J.M.; Hansen, T.; Le Paslier, D.; Linneberg, A.; Nielsen, H.B.; Pel-letier, E.; Renault, P.; Turner, K.; Zhu, H.; Yu, C.; Li, S.; Jian, M.; Zhou, Y.; Li, Y.; Zhang, X.; Li, S.; Qin, N.; Yang, H.; Wang, J.; Brunak, S.; Dore, J.; Guarner, F.; Kristiansen K.; Pedersen, O.; Parkhill, J.; Weissenbach, J.; MetaHIT C.; Bork, P.; Ehr-lich, S.D.; Wang, J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464(7285), 59-65.
266. Ley, R.; Hamady, M.; Lozupone, C.; Turnbaugh, P.; Ramey R.; Bircher, J.; Schlegel, M.L.; Tucker, T.A.; Schrenzel, M.D.; Knight, R.; Gordon, J.I. Evolution of mammals and their gut microbes. Science, 2008, 320(5883), 1647-1651.
267. Cani, P.D.; Delzenne, N.M. The gut microbiome as therapeutic target. Pharmacol. Therapeut., 2011, 130(2), 202-212.
268. Backhed, F.; Ley, R.E.; Sonnenburg, J.L.; Peterson, D.A.; Gordon, J.I. Host-bacterial mutualism in the human intestine. Science, 2005, 307(5717), 1915-1920.
269. Backhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA, 2004, 101(44), 15718-15723.
270. Ley, R.E.; Backhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA, 2005, 102(31), 11070-11075.
271. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 2006, 444(7122), 1027-1031.
272. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: human gut microbes associated with obesity. Nature, 2006, 444(7122), 1022-1023.
273. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Af-fourtit, J.P.; Egholm, M.; Henrissat, B.; Heath, A.C.; Knight, R.; Gordon, J.I. A core gut microbiome in obese and lean twins. Nature, 2009, 457(7228), 480-484.
274. Burcelin, R.; Serino, M.; Chabo, C.; Blasco-Baque, V.; Amar, J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol., 2011, 48(4), 257-273.
275. Backhed, F.; Manchester, J.K.; Semenkovich, C.F.; Gordon, J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA, 2007, 104(3), 979-984.
276. Buchwald, H.; Avidor, Y.; Braunwald, E.; Jensen, M.D.; Pories, W.; Fahrbach, K.; Schoelles, K. Bariatric surgery: a systematic review and meta-analysis. JAMA, 2004, 292(14), 1724-1737.
277. Cummings, D.E.; Overduin, J.; Foster-Schubert, K.E.; Carlson, M.J. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg. Obes. Relat. Dis., 2007, 3(2), 109-115.
278. Rubino, F.; Forgrgione, A.; Cummings, D.E.; Vix, M.; Gnuli, D.; Mingrone, G.; Castagneto, M.; Marescaux, J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann. Surg., 2006, 244(5), 741-749.
279. Caiazzo, R.; Zerrweck, C.; Verhaeghe, R.; Hubert, T.; Amalsteen, L.; Patou, F. Gastric bypass and glucose metabolism. Diabetes Me-tab., 2009, 35(6Pt2), 528-531.
280. Rubanyi, G.M. The future of human gene therapy. Mol. Aspects Med. 2001, 22(3), 113-142.
281. Blaese, R.M.; Culver, K.M.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; Greenblatt, J.J.; Rosenberg, S.A.; Klein, H.; Berger, M.; Mullen, C.A.; Ramsey, W.J.; Muul, L.; Morgan, R.A.; Anderson, W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science, 1995, 270(5235), 475-480.
282. Flotte, T.R. Gene therapy for cystic fibrosis. Curr. Opin. Mol. Ther., 1999, 1(4), 510-516.
283. Anderson, F.W. Reflections: of hope and of concern. Hum. Gene Ther., 1991, 2(3), 193-194.
284. Culver, K.W.; Vickers, T.M.; Lamsam, J.L.; Walling, H.W.; Seregina, T. Gene therapy for solid tumors. Br. Med. Bull., 1995, 51(1), 192-204.
285. Morgan, R.A.; Anderson W.F. Human gene therapy. Annu. Rev. Biochem., 1993, 62, 191-217.
286. Mulligan, R.C. The basic science of gene therapy. Science, 1993, 260(5110), 926-932.
287. Gottschalk, U.; Chan, S. Somatic gene therapy. Present situation and future perspective. Arzneimittelforschung, 1998, 48(11), 1111-1120.
288. Tolstoshev, P. Gene therapy, concepts, current trials and future directions. Annu. Rev. Pharmacol. Toxicol., 1993, 33, 573-596.
289. Bordignon, C.; Notarangelo, L.D.; Nobili, N.; Ferrari, G.; Casorati, G.; Panina, P.; Mazzolari, E.; Maggioni, D.; Rossi, C.; Servida, P.; Ugazio, A.G.; Mavilio, F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science, 1995, 270(5235), 470-475.
290. Feltquate, D.M. DNA vaccines: vector design, delivery, and antigen presentation. J. Cell. Biochem. Suppl., 1998, 30-31, 304-311.
291. Qin, L.; Ding, Y.; Pahud, D.R.; Chang, E.; Imperiale, M.J.; Brom-berg, J.S. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum. Gene Ther., 1997, 8(17), 2019-2029.
292. Kozak, M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem., 1991, 266(30), 19867-19870.
293. Kozak, M. Regulation of translation in eukaryotic systems. Annu. Rev. Cell Biol., 1992, 8, 197-225.
294. Huang, M.T.; Gorman, C.M. Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. Nucleic Acids Res., 1990, 18(4), 937-947.
295. Yew, N.S.; Wysokenski, D.M.; Wang, K.X.; Ziegler, R.J.; Marshall, J.; McNeilly, D.; Cherry, M.; Osburn, W.; Cheng, S.H. Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum. Gene Ther., 1997, 8(5), 575-584.
296. Coleman, M.E.; DeMayo, F.; Yin, K.C.; Lee, H.M.; Geske, R.; Montgomery, C.; Schwartz, R.J. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem., 1995, 270(20), 12109-12116.
297. Anwer, K.; Shi, M.; French, M.F.; Muller, S.R.; Chen, W.; Liu, Q.; Proctor, B.L.; Wang, J.; Mumper, R.J.; Singhal, A.; Rolland, A.P.; Alila, H.W. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. Hum. Gene Ther., 1998, 9(5), 659-670.
298. Gossen, M.; Freundlieb, S.; Bender, G.; Müller, G.; Hillen, W.; Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science, 1995, 268(5218), 1766-1769.
299. Wang, Y.; O'malley, B.W.; Tsai, S.Y. Inducible system designed for future gene therapy. Methods Mol. Biol., 1997, 63, 401-413.
300. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949Pt1), 1465-1468.
301. Romano, G.; Claudino, P.P.; Kaiser, H.E.; Giordano, A. Recent advances, prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy. In vivo, 1998, 12(1), 59-67.
302. Fischer, A. Gene therapy: some results, many problems to solve. Cell Mol. Biol., 2001, 47(8), 1269-1275.
303. Ma, H.; Diamond, S.L. Nonviral gene therapy and its delivery systems. Curr. Pharm. Biotechnol., 2001, 2(1), 1-17.
304. Mahato, R.I.; Smith, L.C.; Rolland, A. Pharmaceutical perspectives of nonviral gene therapy. Adv. Gen., 1999, 41, 95-156.
305. Armentano, D.; Sookdeo, C.; Hehir, K.M.; Gregory, R.J.; St. George, J.A.; Prince, G.A.; Wadsworth, S.C.; Smith, A.E. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther., 1995, 6(10), 1343-1353.
306. Vile, R.G.; Russell, S.J. Retroviruses as vectors. Br. Med. Bull., 1995, 51(1), 12-30.
307. Hodgson, C.P. The vector void in gene therapy. Biotechnology, 1995, 13(3), 222-225.
308. Jain, K.K. Gene therapy for pain. Expert Opin. Biol. Ther., 2008, 8(12), 1855-1866.
309. Langat, D.K.; Mwenda, J.M. Potential risks of viral infections in xenotransplantation. Acta Tropica, 2000, 76(2), 147-158.
310. Bach F.H. Xenotransplantation: problems and prospects. Annu. Rev. Med., 1998, 49, 301-310.
311. Colton, C.K. Implantable biohybrid artificial organs. Cell Transplant., 1995, 4(4), 415-436.
312. Eisenberg, R.S. Genomics in the public domain: strategy and policy. Nat. Genet., 2000, 1(1), 70-74.
313. Bates, S. Progress towards personalized medicine. Drug Discov. Today, 2010, 15(3-4), 115-120.